Certain biomarkers appear to increase risk of death for elderly patients with heart failure symptoms

May 24, 2011, JAMA and Archives Journals

Elderly patients with symptoms of heart failure and increased concentrations in the blood of the biomarker copeptin, or a combination of elevated concentrations of copeptin and the biomarker NT-proBNP, had an associated increased risk of all-cause death, according to a study in the May 25 issue of JAMA.

"A central part in evaluation of with symptoms of is to identify simple tools that can aid the clinician in identifying high-risk and low-risk patients. Combining a biomarker produced locally in the [the of the heart] with a marker produced centrally in the body may be useful in patients with symptoms of heart failure. Studies have consequently tried to establish the clinical use of different markers in the circulation," the authors write.

One such established marker is B-type natriuretic peptide and the N-terminal fragment of its precursor (NT-proBNP). Vasopressin is a non-cardiac plasma marker of cardiovascular disease. The plasma concentration of vasopressin increases in patients with heart failure and is associated with left ventricular dysfunction. Copeptin has emerged as a potential surrogate marker for measurement of vasopressin concentration and may help identify patients with heart failure at high and low risk of death, according to background information in the article.

Urban Alehagen, M.D., Ph.D., of Linkoping University, Linkoping, Sweden and colleagues evaluated the association of combined measurement of plasma copeptin and NT-proBNP concentrations with mortality in an elderly primary care population with symptoms of heart failure. The study included 470 elderly patients in Sweden with heart failure symptoms between January and December 1996. Clinical examination, , and measurement of peptide concentrations were performed, with follow-up through December 2009.

During a median (midpoint) follow-up of 13 years, there were 226 deaths from all causes, including 146 cardiovascular deaths. The mortality distribution across the different measures of copeptin segmented into quartiles (fourths) ranged from 26.5 percent (first quartile) to 46.6 percent (fourth quartile) for cardiovascular mortality and from 38.5 percent (first quartile) to 69.5 percent (fourth quartile) for all-cause mortality. The corresponding distribution for NT-proBNP was 15.9 percent (first quartile) to 56.9 percent (fourth quartile) for cardiovascular mortality and between 28.3 percent (first quartile) to 75.9 percent (fourth quartile) for all-cause mortality.

In models comparing the second, third, and fourth quartiles against the first quartile of the , concentrations of copeptin and NT-proBNP were associated with long-term all-cause mortality, both separately and in combination. Similar results were obtained in models examining . Analysis of data showed all-cause mortality associated with different combinations of copeptin and NT-proBNP, from a group with low plasma concentrations of both markers (group 1, with 63.7 percent survival) to a group with a combination of high plasma concentrations of both markers (group 4, with 16.5 percent survival). Prognostic information obtained by the markers was greater when both were combined.

"The objective of this study was to apply markers in a patient group commonly encountered in primary care, i.e., elderly patients who often present with other diseases, making interpretation of symptoms difficult. The original design of our cohort study did not allow us to assess diagnostic elements of biomarker measurement. Instead, we focused solely on the prognostic information of the markers when applied in a primary care population. These data, together with our findings of the prognostic information provided by measurement of copeptin concentrations in elderly patients with symptoms of heart failure, suggest that vasopressin may be a potential target for therapeutic intervention."

More information: JAMA. 2011;305[20]2088-2095.

Related Stories

Recommended for you

A nanoparticle inhalant for treating heart disease

January 18, 2018
A team of researchers from Italy and Germany has developed a nanoparticle inhalant for treating people suffering from heart disease. In their paper published in the journal Science Translational Medicine, the group describes ...

Starting periods before age of 12 linked to heightened risk of heart disease and stroke

January 15, 2018
Starting periods early—before the age of 12—is linked to a heightened risk of heart disease and stroke in later life, suggests an analysis of data from the UK Biobank study, published online in the journal Heart.

'Decorated' stem cells could offer targeted heart repair

January 10, 2018
Although cardiac stem cell therapy is a promising treatment for heart attack patients, directing the cells to the site of an injury - and getting them to stay there - remains challenging. In a new pilot study using an animal ...

Two simple tests could help to pinpoint cause of stroke

January 10, 2018
Detecting the cause of the deadliest form of stroke could be improved by a simple blood test added alongside a routine brain scan, research suggests.

Exercise is good for the heart, high blood pressure is bad—researchers find out why

January 10, 2018
When the heart is put under stress during exercise, it is considered healthy. Yet stress due to high blood pressure is bad for the heart. Why? And is this always the case? Researchers of the German Centre for Cardiovascular ...

Heart-muscle patches made with human cells improve heart attack recovery

January 10, 2018
Large, human cardiac-muscle patches created in the lab have been tested, for the first time, on large animals in a heart attack model. This clinically relevant approach showed that the patches significantly improved recovery ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.